87 related articles for article (PubMed ID: 12124955)
1. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Lakkis N; Lakiss N; Bobek J; Farmer J
Catheter Cardiovasc Interv; 2002 Aug; 56(4):474-7. PubMed ID: 12124955
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.
Kralisz P; Dobrzycki S; Nowak K; Kochman W; Gajewska-Bachórzewska H; Gugała K; Mezyński G; Prokopczuk P; Zuk J; Korecki J; Poniatowski B; Musiał W
Kardiol Pol; 2004 May; 60(5):459-67. PubMed ID: 15247961
[TBL] [Abstract][Full Text] [Related]
4. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Danzi GB; Capuano C; Sesana M; Baglini R
Catheter Cardiovasc Interv; 2004 Feb; 61(2):179-84. PubMed ID: 14755808
[TBL] [Abstract][Full Text] [Related]
5. Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
Ivandic BT; Kurz K; Keck F; Staritz P; Lehrke S; Katus HA; Giannitsis E
Thromb Haemost; 2008 Oct; 100(4):648-54. PubMed ID: 18841288
[TBL] [Abstract][Full Text] [Related]
6. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
7. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
Valgimigli M; Percoco G; Barbieri D; Ferrari F; Guardigli G; Parrinello G; Soukhomovskaia O; Ferrari R
J Am Coll Cardiol; 2004 Jul; 44(1):14-9. PubMed ID: 15234398
[TBL] [Abstract][Full Text] [Related]
8. Tirofiban for myocardial infarction.
Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
[TBL] [Abstract][Full Text] [Related]
9. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban.
Simon DI; Liu CB; Ganz P; Kirshenbaum JM; Piana RN; Rogers C; Selwyn AP; Popma JJ
Catheter Cardiovasc Interv; 2001 Apr; 52(4):425-32. PubMed ID: 11285593
[TBL] [Abstract][Full Text] [Related]
11. Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions.
Akbulut M; Ozbay Y; Gundogdu O; Dagli N; Durukan P; Ilkay E; Arslan N
Curr Med Res Opin; 2004 Nov; 20(11):1759-67. PubMed ID: 15537476
[TBL] [Abstract][Full Text] [Related]
12. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
Umemura K; Kondo K; Ikeda Y; Nakashima M
Thromb Haemost; 1997 Nov; 78(5):1381-4. PubMed ID: 9408023
[TBL] [Abstract][Full Text] [Related]
13. Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.
Talreja D; Lubbe D; Orford JL; Lennon R; DiBattiste PM; Berger PB
J Thromb Thrombolysis; 2004 Aug; 18(1):25-30. PubMed ID: 15744550
[TBL] [Abstract][Full Text] [Related]
14. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
[TBL] [Abstract][Full Text] [Related]
15. Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
Siotia A; Buckland R; Judge HM; Sastry P; Storey RF
Thromb Haemost; 2006 Jun; 95(6):997-1002. PubMed ID: 16732379
[TBL] [Abstract][Full Text] [Related]
16. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
Lakkis NM; George S; Thomas E; Ali M; Guyer K; Carville D
Catheter Cardiovasc Interv; 2001 Jul; 53(3):346-51. PubMed ID: 11458412
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of two different dosing regimens of tirofiban in citrate or PPACK anticoagulated blood.
Voss R; Grebe M; Pralle H; Tillmanns H; Matzdorff A
Platelets; 2005 Dec; 16(8):492-7. PubMed ID: 16287616
[TBL] [Abstract][Full Text] [Related]
18. Effects of glycoprotein IIb/IIIa inhibition on clinical stabilization parameters in patients with unstable angina and non-Q-wave myocardial infarction.
Okmen E; Cakmak M; Tartan Z; Cam N
Heart Vessels; 2003 Jul; 18(3):117-22. PubMed ID: 12955426
[TBL] [Abstract][Full Text] [Related]
19. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
[TBL] [Abstract][Full Text] [Related]
20. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
